ACTRN12616001005448已完成4 期
Efficacy and safety of dihydroaretemisinin+piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Jamame (Lower Juba) Janale (Lower Shabelle) and Jowhar (Middle Shabelle) sites, Somalia.
Abdullahi Mohamed Hassan0 个研究点目标入组 264 人开始时间: 2016年7月29日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 6 Months 至 60 Years(—)
- 性别
- All
入选标准
- •1. age between six months and 60 years with the exception of 12-17 years old female minors and unmarried females 18 years and above;
- •2. mono-infection with P. falciparum detected by microscopy;
- •3. parasitaemia of 500–200,000/microliter asexual forms;
- •4. presence of axillary temperature greater or equal to 37.5 degrees C or history of fever during the past 24 h
- •5. ability to swallow oral medication;
- •6. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- •7. informed consent from the patient or from a parent or guardian in the case of children aged less than 18 years.
- •8. informed assent from any minor participant aged from 12 to 18 years; and
- •9.. consent for pregnancy testing from married female of 18 years and above.
排除标准
- •1. presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;
- •2. weight under 5 kg;
- •3. mixed or mono-infection with another Plasmodium species detected by microscopy;
- •4. presence of severe malnutrition defined as a child aged 6-60 months has a mid-upper arm circumference below 115 mm)
- •5. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- •6. regular medication, which may interfere with antimalarial pharmacokinetics;
- •7. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
- •8. a positive pregnancy test or breastfeeding of married women aged 18 years and above; and
- •9. unable to or unwilling to take pregnancy test or to use contraception for women of child-bearing age and who are sexually active.
研究者
相似试验
尚未招募
4 期
Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in 6 sentinel sites in IndonesiaInfection - Studies of infection and infectious agentsMalariaACTRN12614000753651Ministry of Health1,200
已完成
4 期
Efficacy and safety of dihydroartemisinin-piperaquine (DP) in Pailin, Preah Vihear and Rattanakiri, and artesunate-mefloquine (ASMQ) in Preah Vihear for uncomplicated P. falciparum malaria and chloroquine (CQ) for P.vivax malaria in the above 3 sites, Cambodia, 2009Infection - Other infectious diseasesMalariaACTRN12612000183886Institude Paster du Cambodge420
尚未招募
4 期
Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in 2 sentinel sites in IndonesiaInfection - Studies of infection and infectious agentsMalariaACTRN12616001533482Ministry of Health of Indonesia352
已完成
4 期
Efficacy and safety of dihydroartemisinin+piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Bosaso, Puntland, Somalia.MalariaACTRN12616000553471Ministry of Health of Puntland88
已完成
4 期
Efficacy and safety of Dihydroartemisinin-Piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in District Headquarter Hospital Zhob of Balochistan province and Tehsil HQ Hospital Sadda Kurram Agency FATA, PakistaMalariaACTRN12615001248550Directorate of Malaria Control, Ministry of National Health Services Regulations and Coordination, NIH, Islamabad176
